Skip to main content
Top
Published in: Critical Care 6/2014

Open Access 01-12-2014 | Commentary

New targets for new therapeutic approaches

Author: Bruno François

Published in: Critical Care | Issue 6/2014

Login to get access

Abstract

Because of its resistance profiles, Pseudomonas aeruginosa remains probably one of the challenging bacteria responsible for ventilator-associated pneumonia in the ICU. Nevertheless, a much better understanding of its mechanism of virulence, such as the type 3 secretion system that can also impact on resistance, gives some opportunities for management improvement. The most promising approach is probably the production of monoclonal antibodies that enable not only more targeted treatments but also development of some early preemptive approaches at the time of colonization through real-time diagnosis.
Literature
1.
go back to reference Sawa T, Shimizu M, Moriyama K, Wiener-Kronish J: Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care 2014, , Sawa T, Shimizu M, Moriyama K, Wiener-Kronish J: Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care 2014, ,
2.
go back to reference El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012, 40: 1157-1163. 10.1097/CCM.0b013e3182377906.CrossRef El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med. 2012, 40: 1157-1163. 10.1097/CCM.0b013e3182377906.CrossRef
3.
go back to reference Van Delden C, Köhler T, Brunner-Ferber F, François B, Carlet J, Pechère JC: Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012, 38: 1118-1125. 10.1007/s00134-012-2559-3.CrossRef Van Delden C, Köhler T, Brunner-Ferber F, François B, Carlet J, Pechère JC: Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012, 38: 1118-1125. 10.1007/s00134-012-2559-3.CrossRef
4.
go back to reference Jackson KD, Starkey M, Kremer S, Parsek MR, Wozniak DJ: Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol. 2004, 186: 4466-4475. 10.1128/JB.186.14.4466-4475.2004.CrossRef Jackson KD, Starkey M, Kremer S, Parsek MR, Wozniak DJ: Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J Bacteriol. 2004, 186: 4466-4475. 10.1128/JB.186.14.4466-4475.2004.CrossRef
5.
go back to reference Mikkelsen H, Sivaneson M, Filloux A: Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ Microbiol. 2011, 13: 1666-1681. 10.1111/j.1462-2920.2011.02495.x.CrossRef Mikkelsen H, Sivaneson M, Filloux A: Key two-component regulatory systems that control biofilm formation in Pseudomonas aeruginosa. Environ Microbiol. 2011, 13: 1666-1681. 10.1111/j.1462-2920.2011.02495.x.CrossRef
6.
go back to reference Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK: Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013, 144: 1759-1767. 10.1378/chest.13-0076.CrossRef Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK: Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013, 144: 1759-1767. 10.1378/chest.13-0076.CrossRef
7.
go back to reference Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P: Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014, 33: 1861-1867. 10.1007/s10096-014-2156-1.CrossRef Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P: Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014, 33: 1861-1867. 10.1007/s10096-014-2156-1.CrossRef
8.
go back to reference François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012, 40: 2320-2326. 10.1097/CCM.0b013e31825334f6.CrossRef François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2012, 40: 2320-2326. 10.1097/CCM.0b013e31825334f6.CrossRef
Metadata
Title
New targets for new therapeutic approaches
Author
Bruno François
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-014-0669-8

Other articles of this Issue 6/2014

Critical Care 6/2014 Go to the issue